Safety issues associated with the use of angiotensin-converting enzyme inhibitors

被引：14

作者：

Ehlers, Mario R. ^{[1
]}

机构：

[1] Pacif Biometr Inc, Seattle, WA 98119 USA

来源：

EXPERT OPINION ON DRUG SAFETY | 2006年 / 5卷 / 06期

关键词：

D O I：

10.1517/14740338.5.6.739

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：739 / 740

页数：2

共 5 条

[1] ACE revisited: A new target for structure-based drug design [J].

Acharya, KR ;

Sturrock, ED ;

Riordan, JF ;

Ehlers, MRW .

NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (11) :891-902

[2] Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors [J].

Adam, A ;

Cugno, M ;

Molinaro, G ;

Perez, M ;

Lepage, Y ;

Agostoni, A .

LANCET, 2002, 359 (9323) :2088-2089

[3] Angiotensin-converting enzyme inhibitor-related angioedema: how to deal with it [J].

Beltrami, Laura ;

Zingale, Lorenza. C. ;

Carugo, Stefano ;

Cicardi, Marco .

EXPERT OPINION ON DRUG SAFETY, 2006, 5 (05) :643-649

[4] Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design [J].

Corradi, HR ;

Schwager, SLU ;

Nchinda, AT ;

Sturrock, ED ;

Acharya, KR .

JOURNAL OF MOLECULAR BIOLOGY, 2006, 357 (03) :964-974

[5] Crystal structure of the human angiotensin-converting enzyme-lisinopril complex [J].

Natesh, R ;

Schwager, SLU ;

Sturrock, ED ;

Acharya, KR .

NATURE, 2003, 421 (6922) :551-554

← 1 →